VivaMed, Syngene Partner to Accelerate AI Drug Validation

Clinical-stage biotech VivaMed BioPharma has entered into a strategic partnership with Syngene International, a global contract research, development and manufacturing organization (CRDMO), to strengthen the validation and development of AI-discovered therapeutic programs.

The collaboration is designed to integrate Syngene’s preclinical development capabilities directly with VivaMed’s artificial intelligence-driven therapeutic hypotheses, creating a streamlined pathway from computational drug discovery to translational validation. By combining advanced analytics with experimental rigor, the companies aim to accelerate the progression of repurposed and improved drug candidates toward clinical development.

VivaMed leverages a proprietary AI engine to analyze large-scale multi-omic datasets, identify novel biomarkers, map drug relationships and uncover high-potential repurposing opportunities. The company’s model is structured around a three-pillar framework: AI-powered discovery, rigorous validation and strategic commercialization.

Under the agreement, Syngene will support in-vitro and in-vivo pharmacology studies, biomarker confirmation, assay development, mechanistic pathway interrogation and translational study design. The collaboration will also include broader preclinical development support, reinforcing reproducibility, intellectual property positioning and regulatory readiness before programs move into clinical stages.

Kendric Speagle, Chief Executive Officer of VivaMed, emphasized that while AI can generate promising hypotheses, experimental validation remains essential. He said the partnership strengthens VivaMed’s validation engine and ensures that its leading programs are developed with the operational discipline required for pharmaceutical partnerships.

Kenneth Barr, Senior Vice President and Head of Strategic Collaborations at Syngene, noted that the collaboration enhances Syngene’s ability to apply a scaled drug development model to repurposed assets. He added that leveraging AI platforms alongside Syngene’s end-to-end research infrastructure could significantly shorten development timelines and improve the efficiency of bringing repurposed therapies to market.

A key aspect of VivaMed’s commercialization strategy involves aligning validated programs with pharmaceutical partner priorities, including the use of regulatory pathways such as 505(b)(2) and biomarker-driven development approaches to create de-risked, scalable opportunities.

The partnership also reflects VivaMed’s broader effort to build a globally integrated, AI-enabled drug development ecosystem. By expanding its network of contract research organizations, academic institutions and pharmaceutical collaborators, the company aims to produce repeatable, partnership-ready therapeutic assets rather than operate as a closed discovery platform.

As AI continues to reshape drug discovery, the VivaMed–Syngene collaboration highlights a growing industry focus on combining computational innovation with robust translational science to deliver credible, development-ready candidates for patients worldwide.